Nothing Special   »   [go: up one dir, main page]
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 5
2010 3
2011 7
2012 2
2013 3
2014 5
2015 12
2016 11
2017 7
2018 8
2019 8
2020 11
2021 9
2022 12
2023 8
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean sang won lee (903 results)?
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Progress in Malassezia Research in Korea.
Kim SY, Lee YW, Choe YB, Ahn KJ. Kim SY, et al. Among authors: lee yw. Ann Dermatol. 2015 Dec;27(6):647-57. doi: 10.5021/ad.2015.27.6.647. Epub 2015 Dec 7. Ann Dermatol. 2015. PMID: 26719632 Free PMC article. Review.
Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
Seok J, Koh YG, Hong JK, Yun SH, Kim DH, Son HS, Choi SY, Yoo KH, Lee YW, Kim BJ. Seok J, et al. Among authors: lee yw. Dermatol Surg. 2024 Jun 1;50(6):527-533. doi: 10.1097/DSS.0000000000004146. Epub 2024 Mar 8. Dermatol Surg. 2024. PMID: 38518110 Clinical Trial.
A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians.
Choi SY, Koh YG, Lee YW, Son HS, Yoon YN, Kim G, Won C, Cho H, Son JS, Kim EK, Kim BJ. Choi SY, et al. Among authors: lee yw. J Dermatolog Treat. 2024 Dec;35(1):2359511. doi: 10.1080/09546634.2024.2359511. Epub 2024 Jun 16. J Dermatolog Treat. 2024. PMID: 38880494 Free article. Clinical Trial.
Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD).
Park CW, Kim BJ, Lee YW, Won C, Park CO, Chung BY, Lee DH, Jung K, Nam HJ, Choi G, Park YH, Kim KH, Park M. Park CW, et al. Among authors: lee yw. J Allergy Clin Immunol. 2022 Apr;149(4):1340-1347.e4. doi: 10.1016/j.jaci.2021.09.024. Epub 2021 Oct 2. J Allergy Clin Immunol. 2022. PMID: 34606832 Free article. Clinical Trial.
Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.
Guttman-Yassky E, Bahadori L, Brooks L, Clark KL, Grindebacke H, Ho CN, Katial R, Pham TH, Walton C, Datto CJ; HILLIER study group†. Guttman-Yassky E, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1211-e1214. doi: 10.1111/jdv.19195. Epub 2023 Jun 12. J Eur Acad Dermatol Venereol. 2023. PMID: 37178404 Clinical Trial. No abstract available.
106 results